Change search
ReferencesLink to record
Permanent link

Direct link
Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
Daiichi Sankyo Pharma Dev, Translat Med & Clin Pharmacol, Modeling & Simulat, Edison, NJ USA..
Show others and affiliations
2016 (English)In: CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, ISSN 2163-8306, Vol. 5, no 4, 222-232 p.Article in journal (Refereed) Published
Abstract [en]

Edoxaban exposure-response relationships from the phase III study evaluating edoxaban for prevention and treatment of venous thromboembolism (VTE) in patients with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE) were assessed by parametric time-to-event analysis. Statistical significant exposure-response relationships were recurrent VTE with hazard ratio (HR) based on average edoxaban concentration at steady state (C-av) (HRCav) 50.98 (i.e., change in the HR with every 1 ng/mL increase of C-av); the composite of recurrent DVT and nonfatal PE with HRC(av)50.99; and the composite of recurrent DVT, nonfatal PE, and all-cause mortality HRC(av)50.98, and all death using maximal edoxaban concentration (C-max) with HR (C-max) 50.99. No statistical significant exposure-response relationships were found for clinically relevant bleeding or major adverse cardiovascular event. Results support the recommendation of once-daily edoxaban 60 mg, and a reduced 30 mg dose in patients with moderate renal impairment, body weight <= 60 kg, or use of P-glycoprotein inhibitors verapamil or quinidine.

Place, publisher, year, edition, pages
2016. Vol. 5, no 4, 222-232 p.
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:uu:diva-303402DOI: 10.1002/psp4.12077ISI: 000381564500007PubMedID: 27299709OAI: oai:DiVA.org:uu-303402DiVA: diva2:971754
Available from: 2016-09-19 Created: 2016-09-19 Last updated: 2016-09-19Bibliographically approved

Open Access in DiVA

fulltext(1028 kB)12 downloads
File information
File name FULLTEXT01.pdfFile size 1028 kBChecksum SHA-512
aaa6e9f65c634b68e473a93e2cc87cc2550f00ae94e13e8f788455c7e4fc110bffe2d813b0d532d5cdb7e65475b867bd1b54e448e3c27aff56c44a15d8ea507d
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Karlsson, Mats O.Simonsson, Ulrika S. H.
By organisation
Department of Pharmaceutical Biosciences
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar
Total: 12 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 12 hits
ReferencesLink to record
Permanent link

Direct link